Section Arrow
SABS.NASDAQ
- SAB Biotherapeutics
Quotes are at least 15-min delayed:2024/06/24 08:21 EDT
Last
 2.75
-0.02 (-0.72%)
Day High 
3.18 
Prev. Close
2.77 
1-M High
3.5 
Volume 
17.82K 
Bid
1.97
Ask
3.48
Day Low
2.71 
Open
2.71 
1-M Low
2.36 
Market Cap 
25.57M 
Currency USD 
P/E -- 
%Yield
10-SMA 3.08 
20-SMA 2.89 
50-SMA 3.65 
52-W High 10.5 
52-W Low 2.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.72/-3.12
Enterprise Value
29.62M
Balance Sheet
Book Value Per Share
5.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MBIOMustang Bio0.5594-0.0011-0.20%-- 
DNAGinkgo Bioworks Holdings0.4244+0.0157+3.84%-- 
KTRAKintara Therapeutics0.2472-0.0277-10.08%-- 
BMRNBioMarin Pharmaceutical83.72-0.99-1.17%79.92PE
QLGNQualigen Therapeutics0.222+0.0449+25.35%-- 
Quotes are at least 15-min delayed:2024/06/24 08:21 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.